Discovery and validation of new osteoarthritis biomarkers using OMICs approaches across the spectrum of disease by Sanchez, Christelle
Discovery and validation of new 
osteoarthritis biomarkers using 
omics approaches across the 
spectrum of disease
Christelle Sanchez
Bone and Cartilage Research Unit, 










+ Target of biomarker follow-up    vs      + Joint specificity
- Depletion of majors proteins + Pathological pathways (inflammation,…)























Quantitative proteomics : The state of the art
Gharbi M., Deberg M., Henrotin Y., Application for Proteomic Techniques in Studying Osteoarthritis: A Review, 
Front Physiol. 2011; 2: 90
Overview of the different wokflows
Biomarker Discovery: 






• Small number of 
samples (3 to 10)
• Looking at ± 1000 
proteins at once 
without any a priori
• Complex, expensive 
and time consuming 
analysis
• Average number of 
samples from 10 to 
100
• Alternative methods
• Looking at  specific 
proteins (10-100)
• Targeted quite 
complex and 
expensive methods
• Average number of 
samples greater than 
100
• Immuno-based high 
throughput tests
• Looking at  specific 
proteins (<100)
• Targeted and 
multiplex (low cost 
screening tests)
Identification of Fibulin-3 peptides as biomarkers of OA
Henrotin Y et al Arthritis Rheum 2012, 64(7):2260-2267
Exemple of proteomic application in new OA biomarker research:
Fibulin 3 peptides Fib3-1 and Fib3-2 are 
potential biomarkers of osteoarthritis
– Proteomic analysis of human urines by 2D-DIGE
– Identification of proteins or fragments of interest by mass 
spectrometry
– Production of specific antiserum directed against identified 
peptides
– Development of specific immunoassay of peptides







Serpins b1 et b3











Henrotin et al. Arthritis Rheum 2012
OA/N > 1.5
OA/N > 0.7
Proteomic analysis: classical workflow of protein identification
Fibulin-3: relation with cartilage
 Extracellular matrix protein highly expressed in cartilaginous tissue (Timpl,
et al. 2003; Kobayashi, et al. 2007)
 Expressed in the mesenchyme giving rise to cartilage and bone, and
plays a role in organizing the development of skeletal system (Ehlermann
et al., 2003)
 Identified in OA cartilage by proteomic analysis (Vincourt et al., 2006)
 Intimately associated with (TIMP)-3, an inhibitor of metalloproteinases
involved in the pathogenesis of OA (Klenotic et al., 2004 ; Kevorkian et al.,
2004 ; Sahebjam et al., 2007)
 Negative regulator of chondrocytes differentiation (Wakabayashi, et al.
2010)






Specific immunoassays of Fib3-1 
and Fib3-2 development and 
validation in human serum
Fib 3-2:ROC curve












































Fib3-1 (cut-off:  71.1 pM) 78.5% 68.4%
Fib3-2 (cut-off: 163.7 pM) 75.0% 86.4%






























































W4   n=5
Control group   W16 n=2
W35 n=10
Guinea pig as spontaneous model of OA
Fib3-2 kinetic in sera and correlation with histology
Recommanded OARSI histological OA score for 
guinea pig, parametric ANOVA /Dunnett’s post test
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35-week old guinea pig, right knee, medial
Proteomic paradox
Recovery of unknown proteins in chondrocytes - cartilage matrix
AND
Some known proteins are not found!
Example : 
Rosenthal et al (2011) investigated protein pattern present 
in articular cartilage vesicles (AVCs) and didn’t find 
TNALP or PC1, well known enzymes located in their membrane
Due to their structure/composition/localisation, 
Lot of proteins are undetectable with current technics

Quantitative proteomics : a discipline in constant progress
 Sample preparation method / Specific depletions
 Protein labeling – label free methods
 Improvement in protein separation
 Protein fractionation method  
 Sensibility of detection











 New OMICs technologies flood us with new
potential biomarkers
 Validation and qualification of one potential
biomarker is a very long and expensive process
 It’s essential to start OMICs studies with the
good samples – representative – homogen…to
gives us important informations - maybe on
subgroups of the disease
Thank you !
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